Lipoprotein(a): An Emerging Cardiovascular Risk Factor

REFERENCES

• Fuster V. Epidemic of cardiovascular disease and stroke: the three main challenges. Presented at the 71st scientific sessions of the American Heart Association. Dallas, Texas. Circulation 1999; 99: 1132–1137.
   PubMed Web of Science ®Google Scholar
• Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. Br Med J 2000; 320: 659–661.
   PubMedGoogle Scholar
• Superko HR. Did grandma give you heart disease? The new battle against coronary artery disease. Am J Cardiol 1998; 82: 34Q-46Q.
   Google Scholar
• Futterman LG, Lemberg L. Fifty percent of patients with coronary artery disease do not have any of the conventional risk factors. Am J Crit Care 1998; 7: 240–244.
   PubMedGoogle Scholar
• Lonn EM, Yusuf S. Evidence based cardiology: emerging approaches in preventing cardiovascular disease. Br Med J 1999; 318: 1337–1341.
   PubMedGoogle Scholar
• Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med 2000; 45: 391–418.
   PubMedGoogle Scholar
• Poulter NR. Benefits and pitfalls of cardiovascular risk assessment. J Hum Hypertens 2000; 14 Suppl 2: S11–16.
   Google Scholar
• Lefkowitz RJ, Willerson JT. Prospects for cardiovascular research. JAMA 2001; 285: 581–587.
   PubMedGoogle Scholar
• Seman LJ, McNamara JR, Schaefer EJ. Lipoprotein(a), homocysteine, and remnantlike particles: emerging risk factors. Curr Opin Cardiol 1999; 14: 186–191.
   PubMedGoogle Scholar
• Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocys-teine, lipoprotein(a), triglycerides, oxidative stress and fibrinogen. Ann Intern Med 1999; 131: 376–386.
   PubMed Web of Science ®Google Scholar
• Lippi G, Lo Cascio C, Ruzzenente O, Poli G, Brentegani C, Guidi G. Simple and rapid procedure for the purification of lipoprotein(a). J Chromatogr B 1996; 682: 225–231.
   PubMedGoogle Scholar
• Fless GM, ZumMallen ME, Scanu AM. Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a). J Biol Chem 1986; 261: 8712–8718.
   PubMed Web of Science ®Google Scholar
• McLean JW, Tomlinson JE, Kuang W-J et al. cDNA sequence of human lipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132–137.
   PubMed Web of Science ®Google Scholar
• Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993; 2: 933–940.
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American Blacks and Whites. Biochem Biophys Res Commun 1993; 191: 1192–1196.
   PubMed Web of Science ®Google Scholar
• Pati U, Pati N. Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism. Mol Genet Metab 2000; 71: 87–92.
   PubMedGoogle Scholar
• Ramharack R, Spahr MA, Kreick JS, Sekerke CS. Expression of apolipoprotein[a] and plasminogen mRNAs in cynomolgus monkey liver and extrahepatic tissues. J Lipid Res 1996; 37: 2029–2040.
   PubMedGoogle Scholar
• Fu L, Jamiesn DG, Usher DC, Lavi E. Gene expression of apolipoprotein(a) within the wall of human aorta and carotid arteries. Atherosclerosis 2001; 158: 303–311.
   PubMedGoogle Scholar
• White AL, Guerra B, Lanford RE. Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. J Biol Chem 1997; 272: 5048–5055.
   PubMed Web of Science ®Google Scholar
• Braakman I, Helenius J, Helenius A. Role of ATP and disulfide bonds during protein folding in the endoplasmic reticulum. Nature 1992; 356: 260–262.
   PubMed Web of Science ®Google Scholar
• Bonen DK, Hausman AM, Hadjiagapiou C, Skarosi SF, Davidson NO. Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). J Biol Chem 1997; 272: 5659–5667.
   PubMed Web of Science ®Google Scholar
• Dieplinger H, Utermann G. The seventh myth of lipoprotein(a): where and how is it assembled? Curr Opin Lipidol 1999; 10: 275–283.
   PubMedGoogle Scholar
• Lobentanz EM, Krasznai K, Gruber A et al. Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells. Biochemistry 1998; 37: 5417–5425.
   PubMed Web of Science ®Google Scholar
• White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem 1994; 269: 28716–28723.
   PubMed Web of Science ®Google Scholar
• Hrzenjak A, Frank S, Maderegger B, Sterk H, et al. Apo(a)-kringle IV-type 6: expression in escherichia coli, purification and in vitro refolding. Protein Eng 2000; 13: 661–666.
   PubMedGoogle Scholar
• McCormick SP, Ng JK, Taylor S, et al. Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). Proc Natl Acad Sci USA 1995; 92: 10147–10151.
   PubMedGoogle Scholar
• Callow MJ, Rubin EM. Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo. J Biol Chem 1995; 270: 23914–23917.
   PubMedGoogle Scholar
• Gabel BR, Koschinsky ML. Sequences within apolipoprotein(a) kringle IV types 6-8 bind directly to low-density lipoprotein and mediate noncovalent association of apolipoprotein(a) with apolipoprotein B-100. Biochemistry 1998; 37: 7892–7898.
   PubMedGoogle Scholar
• Cheesman EJ, Sharp RJ, Zlot CH et al. An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a). J Biol Chem 2000; 275: 28195–28200.
   PubMedGoogle Scholar
• Becker L, McLeod RS, Marcovina SM, Yao Z, Koschinsky ML. Identification of a critical lysine residue in apolipoprotein B-100 that mediates noncovalent interaction with apolipoprotein(a). J Biol Chem 2001; 276: 36155–36162.
   PubMed Web of Science ®Google Scholar
• Xu S. Apolipoprotein(a) binds to low-density lipoprotein at two distant sites in lipoprotein(a). Biochemistry 1998; 37: 9284–9294.
   PubMedGoogle Scholar
• Weisel JW, Nagaswami C, Woodhead JL, et al. The structure of lipoprotein(a) and ligand-induced conformational changes. Biochemistry 2001 40: 10424–10435.
   PubMedGoogle Scholar
• Fless GM, Pfaffinger DJ, Eisenbart JD, Scanu AM. Solubility, immunochemical, and lipopro-tein binding properties of apoB-100-apo[a], the protein moiety of lipoprotein[a]. J Lipid Res 1990; 31: 909–918.
   PubMed Web of Science ®Google Scholar
• Rader DJ, Mann WA, Cain W, et al. The low-density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95: 1403–1408.
   PubMed Web of Science ®Google Scholar
• Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest 1990; 85: 1542–7.
   PubMed Web of Science ®Google Scholar
• Marz W, Beckmann A, Scharnagl H et al. Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. FEBS Lett 1993; 325: 271–275.
   PubMed Web of Science ®Google Scholar
• Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK. The atherogenic lipopro-tein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997; 100: 2170–2181.
   PubMed Web of Science ®Google Scholar
• Reblin T, Niemeier A, Meyer N et al. Cellular uptake of lipoprotein(a) by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein. J Lipid Res 1997; 38: 2103–2110.
   PubMedGoogle Scholar
• Niemeier A, Willnow T, Dieplinger H et al. Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro. Arterioscler Thromb Vasc Biol 1999; 19: 552–561.
   PubMed Web of Science ®Google Scholar
• Fan J, Challah M, Shimoyamada H, Shiomi M, Marcovina S, Watanabe T. Defects of the LDL receptor in WHHL transgenic rabbits lead to a marked accumulation of plasma lipoprotein[a]. J Lipid Res 2000; 41: 1004–1012.
   PubMedGoogle Scholar
• Hughes SD, Lou XJ, Ighani S et al. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 1997; 100: 1493–1500.
   PubMed Web of Science ®Google Scholar
• Higazi AA, Lavi E, Bdeir K et al. Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood 1997; 89: 4290–4298.
   PubMed Web of Science ®Google Scholar
• Bottalico LA, Keesler GA, Fless GM, Tabas I. Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation. J Biol Chem 1993; 268: 8569–8573.
   PubMedGoogle Scholar
• Keesler GA, Gabel BR, Devlin CM, Koschinsky ML, Tabas I. The binding activity of the macrophage lipoprotein(a)/apolipoprotein(a) receptor is induced by cholesterol via a post-translational mechanism and recognizes distinct kringle domains on apolipoprotein(a). J Biol Chem 1996; 271: 32096–32104.
   PubMedGoogle Scholar
• Skiba PJ, Keesler GA, Tabas I. Interferon-gamma down-regulates the lipoprotein(a)/ apoprotein(a) receptor activity on macrophage foam cells. Evidence for disruption of ligand-induced receptor recycling by interferon-gamma. J Biol Chem 1994; 269: 23059–23067.
   PubMedGoogle Scholar
• Lippi G, Braga V, Adami S, Guidi G. Modification of serum apolipoprotein A-I, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response. Clin Chim Acta 1998; 271: 79–87.
   PubMedGoogle Scholar
• Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med 1999; 340: 115–126.
   PubMed Web of Science ®Google Scholar
• Hughes S. Novel risk factors for coronary heart disease: emerging connections. J Cardiovasc Nurs 2000; 14: 91–103.
   PubMedGoogle Scholar
• Frank S, Hrzenjak A, Blaschitz A, Dohr G, Kostner GM. Role of various tissues in apo(a) fragmentation and excretion of fragments by the kidney. Eur J Clin Invest 2001; 31: 504–512.
   PubMed Web of Science ®Google Scholar
• Edelstein C, Italia JA, Scanu AM. Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments. J Biol Chem 1997; 272: 11079–11087.
   PubMedGoogle Scholar
• Scanu AM, Edelstein C. Learning about the structure and biology of human lipoprotein [a] through dissection by enzymes of the elastase family: facts and speculations. J Lipid Res 1997; 38: 2193–2206.
   PubMedGoogle Scholar
• Edelstein C, Shapiro SD, Klezovitch O, Scanu AM. Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. Potential relevance to lipoprotein(a) biology. J Biol Chem 1999; 274: 10019–10023.
   Google Scholar
• Frank SL, Klisak I, Sparkes RS et al. The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen. Hum Genet 1988; 79: 352–356.
   PubMedGoogle Scholar
• Lawn RM. How often has Lp(a) evolved? Clin Genet 1996; 49: 167–174.
   PubMed Web of Science ®Google Scholar
• Lawn RM, Boonmark NW, Schwartz K et al. The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a). J Biol Chem 1995; 270: 24004–24009.
   PubMedGoogle Scholar
• Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol 1999; 10: 133–141.
   PubMed Web of Science ®Google Scholar
• Magnaghi P, Citterio E, Malgaretti N, Acquati F, Ottolenghi S, Taramelli R. Molecular characterisation of the human apo(a)-plasminogen gene family clustered on the telomeric region of chromosome 6 (6q26-27). Hum Mol Genet 1994; 3: 437–442.
   PubMedGoogle Scholar
• Byrne CD, Schwartz K, Meer K, Cheng JF, Lawn RM. The human apolipoprotein(a)/plasminogen gene cluster contains a novel homologue transcribed in liver. Arterioscler Thromb 1994; 14: 534–541.
   PubMedGoogle Scholar
• Yamamura Y, Yamashiro K, Tsuruoka N, Nakazato H, Tsujimura A, Yamaguchi N. Molecular cloning of a novel brain-specific serine protease with a kringle-like structure and three scavenger receptor cysteine-rich motifs. Biochem Biophys Res Commun 1997; 239: 386–392.
   PubMedGoogle Scholar
• Boerwinkle E, Leffert C, Lin J, Lackner C, Chiesa G, Hobbs H. Apolipoprotein(a) gene accounts for greater that 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52–60.
   PubMed Web of Science ®Google Scholar
• Perombelon YF, Soutar AK, Knight BL. Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles. J Clin Invest 1994; 93: 1481–1492.
   PubMed Web of Science ®Google Scholar
• Gavish D, Azrolan N, Breslow JL. Plasma Lp(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene. J Clin Invest 1989; 84: 2021–2027.
   PubMedGoogle Scholar
• Wade DP, Puckey LH, Knight BL, Acquati F, Mihalich A, Taramelli R. Characterization of multiple enhancer regions upstream of the apolipoprotein(a) gene. J Biol Chem 1997; 272: 30387–30399.
   PubMedGoogle Scholar
• Ogorelkova M, Gruber A, Utermann G. Molecular basis of congenital lp(a) deficiency: a frequent apo(a) ‘null’ mutation in caucasians. Hum Mol Genet 1999; 8: 2087–2096.
   PubMed Web of Science ®Google Scholar
• Valenti K, Aveynier E, Leaute S, Laporte F, Hadjian AJ. Contribution of apolipoprotein(a) size, pentanucleotide TTTTA repeat and C/T(+93) polymorphisms of the apo(a) gene to regulation of lipoprotein(a) plasma levels in a population of young European Caucasians. Atherosclerosis 1999; 147: 17–24.
   PubMedGoogle Scholar
• Wade DP, Lindahl GE, Lawn RM. Apolipoprotein(a) gene transcription is regulated by liver-enriched trans-acting factor hepatocyte nuclear factor 1?. J Biol Chem 1994; 269: 19757–19765.
   PubMedGoogle Scholar
• Yang Z, Boffelli D, Boonmark N, Schwartz K, Lawn R. Apolipoprotein(a) gene enhancer resides within a LINE element. J Biol Chem 1998; 273: 891–897.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 1996; 33: 495–543.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Giugno I, Trovato BA, Panebianco MP, Restuccia N, Ruello P. Lipoprotein(a) in cirrhosis. A new index of liver functions? Curr Med Res Opin 1996; 13: 479–485.
   Google Scholar
• Ciccarese M, Tonolo G, Brizzi P et al. Serum apolipoprotein(a) concentrations and Apo(a) phenotypes in patients with liver cirrhosis. Am J Gastroenterol 1998; 93: 1505–1509.
   PubMedGoogle Scholar
• Oida K, Takai H, Maeda H et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 1992; 38: 2244–2248.
   PubMed Web of Science ®Google Scholar
• Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina S, Hobbs HH. Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). J Clin Invest 1996; 97: 858–864.
   PubMed Web of Science ®Google Scholar
• Kostner KM, Maurer G, Huber K et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996; 16: 905–911.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Berglund L. Lipoprotein(a) in chronic renal disease. Miner Electrolyte Metab 1996; 22: 16–21.
   PubMedGoogle Scholar
• Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996; 27: 1–25.
   PubMed Web of Science ®Google Scholar
• Kostner KM, Oberbauer R, Hoffmann U, Stefenelli T, Maurer G, Watschinger B. Urinary excretion of apo(a) in patients after kidney transplantation. Nephrol Dial Transplant 1997; 12: 2673–2678.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Trenkwalder E, Lingenhel A, Kayser GA, et al. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res 1997; 38: 1755–1763.
   PubMed Web of Science ®Google Scholar
• De Sain-Van Der Velden MG, Reijngoud DJ, Kaysen GA, et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 1998; 9: 1474–1481.
   PubMedGoogle Scholar
• Nakahara C, Nagata M, Watanabe T, et al. Clinical significance of apolipoprotein (a) deposition in kidney diseases of children. Clin Nephrol 1999; 52: 131–138.
   PubMedGoogle Scholar
• Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997; 11: 341–355.
   PubMed Web of Science ®Google Scholar
• Rossouw JE. Hormone replacement therapy and cardiovascular disease. Curr Opin Lipidol 1999; 10: 429–434.
   PubMedGoogle Scholar
• Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ. Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. Atherosclerosis 1996; 122: 89–95.
   PubMed Web of Science ®Google Scholar
• Lippi G, Guidi G, Ruzzenente O, Braga V, Adami S. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis. Scand J Clin Lab Invest 1997; 57: 507–511.
   PubMed Web of Science ®Google Scholar
• Boffelli D, Zajchowski DA, Yang Z, Lawn RM. Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element. J Biol Chem 1999; 274: 15569–15574.
   PubMedGoogle Scholar
• Paassilta M, Karjalainen A, Kervinen K, et al. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. Atherosclerosis 2000; 149: 157–162.
   PubMed Web of Science ®Google Scholar
• Heller FR, Jamart J, Honore P, et al. Serum lipoprotein(a) in patients with diabetes mellitus. Diabetes Care 1993; 16: 819–823.
   PubMedGoogle Scholar
• Morishita E, Asakura H, Jokaji H, et al. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 1996; 120: 7–14.
   PubMedGoogle Scholar
• Durlach V, Gillery P, Bertin E, Grulet H, Gross A, Leutenegger M. Influence of endogenous and environmental factors on variations of serum lipoprotein (a) concentrations in a large population of insulin-treated diabetic patients. Diabetes Metab 1998; 24: 124–130.
   PubMedGoogle Scholar
• Chang CJ, Kao JT, Wu TJ, Lu FH, Tai TY. Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients. Relation to metabolic control. Diabetes Care 1995; 18: 1191–1194.
   PubMedGoogle Scholar
• Durlach V, Gillery P, Bertin E, et al. Serum lipoprotein (a) concentrations in a population of 819 non-insulin-dependent diabetic patients. Diabetes Metab 1996; 22: 319–323.
   PubMed Web of Science ®Google Scholar
• Torres-Tamayo M, Zamora-Gonzalez J, Bravo-Rios LE, Cardoso-Saldana G, Mendoza-Morfin F, Posadas-Romero C. Lipoprotein(a) levels in children and adolescents with diabetes. Rev Invest Clin 1997; 49: 437–443.
   PubMedGoogle Scholar
• Song KH, Ahn YB, Yoon KH, et al. The effect of long-term glycaemic control on serum lipoprotein(a) levels in patients with Type 2 diabetes mellitus. Diabet Med 1999; 16: 1036–1039.
   PubMedGoogle Scholar
• Wollesen F, Dahlen G, Berglund L, Berne C. Peripheral atherosclerosis and serum lipoprotein(a) in diabetes. Diabetes Care 1999; 22: 93–98.
   PubMedGoogle Scholar
• Jenkins AJ, Best JD. The role of lipoprotein(a) in the vascular complications of diabetes mellitus. J Intern Med 1995; 237: 359–365.
   PubMedGoogle Scholar
• Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000; 10: 803–808.
   PubMed Web of Science ®Google Scholar
• Engler H, Riesen WF. Effect of thyroid function on concentrations of lipoprotein(a). Clin Chem 1993; 39: 2466–2469.
   PubMed Web of Science ®Google Scholar
• Maldonado Castro GF, Escobar-Morreale HF, Ortega H, et al. Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. Clin Endocrinol (Oxford) 2000; 53: 313–319.
   PubMed Web of Science ®Google Scholar
• Lam KSL, Pang RWC, Janus ED, Kung AWC, Wang CLC. Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly. Atherosclerosis 1993; 104: 183–188.
   PubMedGoogle Scholar
• Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE. Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a). Eur J Endocrinol 1997; 136: 377–381.
   PubMed Web of Science ®Google Scholar
• Bianda T, Schmid C. Effects of short-term treatment with insulin-like growth factor-I and growth hormone on serum lipoprotein (a) in growth hormone-deficient adults. Eur J Endocrinol 1998; 138: 189–190.
   PubMedGoogle Scholar
• Tao R, Acquati F, Marcovina SM, Hobbs HH. Human growth hormone increases apo(a) expression in transgenic mice. Arterioscler Thromb Vasc Biol 1999; 19: 2439–2447.
   PubMedGoogle Scholar
• Wolthers T, Lemming L, Grofte T, et al. Effects of growth hormone on serum lipids and lipoproteins: possible significance of increased peripheral conversion of thyroxine to triiodot-hyronine. Metabolism 1996; 45: 1016–1020.
   PubMedGoogle Scholar
• Wassef GN. Lipoprotein (a) in android obesity and NIDDM: a new member in ‘the metabolic syndrome’. Biomed Pharmacother 1999; 53: 462–465.
   PubMedGoogle Scholar
• Ramharack R, Barkalow D, Spahr MA. Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol 1998; 18: 984–990.
   PubMed Web of Science ®Google Scholar
• Min WK, Chun S, Hwang SH, Park H. No relationship between serum lipoprotein(a) and albumin concentrations in patients with acute phase response. Ann Clin Biochem 1999; 36: 617–621.
   PubMed Web of Science ®Google Scholar
• Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY. The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chim Acta 1993; 223: 73–82.
   PubMed Web of Science ®Google Scholar
• Noma A, Abe A, Maeda S, et al. Lp(a): an acute-phase reactant? Chem Phys Lipids 1994; 67-68: 411–417.
   Google Scholar
• Orem A, Deger O, Cimsit G, Karahan SC, Akyol N, Yildirmis S. Plasma Lipoprotein(a) and its relationship with disease activity in patients with Behcet’s disease. Eur J Clin Chem Clin Biochem 1995; 33: 473–478.
   PubMedGoogle Scholar
• Min WK, Lee JO, Huh JW. Relation between lipoprotein(a) concentrations in patients with acute-phase response and risk analysis for coronary heart disease. Clin Chem 1997; 43: 1891–1895.
   PubMed Web of Science ®Google Scholar
• Durstine JL, Ferguson MA, Szymanski LM, et al. Effect of a single session of exercise on lipoprotein(a). Med Sci Sports Exerc 1996; 28: 1277–1281.
   PubMedGoogle Scholar
• Mackinnon LT, Hubinger LM. Effects of exercise on lipoprotein(a). Sports Med 1999; 28: 11–24.
   PubMedGoogle Scholar
• Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21 Suppl 1: S5–S9.
   Google Scholar
• Mackinnon LT, Hubinger L, Lepre F. Effects of physical activity and diet on lipoprotein(a). Med Sci Sports Exerc 1997; 29: 1429–1436.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Tzotzas T, Giral P, et al. Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program. Nutr Metab Cardiovasc Dis 2001; 11: 153–157.
   PubMed Web of Science ®Google Scholar
• Zock PL, Katan MB. Trans fatty acids, lipoproteins, and coronary risk. Can J Physiol Pharmacol 1997; 75: 211–216.
   PubMed Web of Science ®Google Scholar
• Clevidence BA, Judd JT, Schaefer EJ, et al. Plasma lipoprotein (a) levels in men and women consuming diets enriched in saturated, cis-, or trans-monounsaturated fatty acids. Arterioscler Thromb Vasc Biol 1997; 17: 1657–1661.
   PubMedGoogle Scholar
• Marcovina SM, Kennedy H, Bittolo Bon G, et al. Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania: The Lugalawa Study. Arterioscler Thromb Vasc Biol 1999; 19: 1250–1256.
   PubMedGoogle Scholar
• Nilausen K, Meinertz H. Lipoprotein(a) and dietary proteins: casein lowers lipoprotein(a) concentrations as compared with soy protein. Am J Clin Nutr 1999; 69: 419–425.
   PubMedGoogle Scholar
• Sharpe PC, McGrath LT, McClean E, Young IS, Archbold GP. Effect of red wine consumption on lipoprotein (a) and other risk factors for atherosclerosis. QJM 1995; 88: 101–108.
   PubMed Web of Science ®Google Scholar
• Paassilta M, Kervinen K, Linnaluoto M, Kesaniemi YA. Alcohol withdrawal-induced change in lipoprotein(a): association with the growth hormone/insulin-like growth factor-I (IGF-I)/IGF-binding protein-1 (IGFBP-1) axis. Arterioscler Thromb Vasc Biol 1998; 18: 650–654.
   PubMedGoogle Scholar
• Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904–910.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature 1987; 330: 113–114.
   PubMed Web of Science ®Google Scholar
• Yano Y, Shimokawa K, Okada Y, Noma A. Immunolocalization of lipoprotein(a) in wounded tissues. J Histochem Cytochem 1997; 45: 559–568.
   PubMedGoogle Scholar
• van der Hoek YY, Sangrar W, Cote GP, Kastelein JJ, Koschinsky ML. Binding of recombinant apolipoprotein(a) to extracellular matrix proteins. Arterioscler Thromb 1994; 14: 1792–1798.
   PubMedGoogle Scholar
• Edelberg JM, Pizzo SV. Lipoprotein (a) in the regulation of fibrinolysis. J Atheroscler Thromb 1995; 2 Suppl 1: S5–7.
   Google Scholar
• Ribatti D, Vacca A, Giacchetta F, et al. Lipoprotein (a) induces angiogenesis on the chick embryo chorioallantoic membrane. Eur J Clin Invest 1998; 28: 533–537.
   PubMedGoogle Scholar
• Rath M, Pauling L. Hypothesis: lipoprotein(a) is a surrogate for ascorbate. Proc Natl Acad Sci USA 1990; 87: 6204–6207.
   PubMed Web of Science ®Google Scholar
• Jenner JL, Jacques PF, Seman LJ, Schaefer EJ. Ascorbic acid supplementation does not lower plasma lipoprotein(a) concentrations. Atherosclerosis 2000; 151: 541–544.
   PubMedGoogle Scholar
• Lippi G, Guidi G. Lipoprotein(a): from ancestral benefit to modern pathogen? QJM 2000; 93: 75–84.
   Google Scholar
• O’Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 1997; 79: 273–294.
   PubMedGoogle Scholar
• Thillet J, Doucet C, Chapman J, Herbeth B, Cohen D, Faure-Delanef L. Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: evidence from a large population of French centenarians. Atherosclerosis 1998; 136: 389–394.
   PubMedGoogle Scholar
• Fischer MB, Roeckl C, Parizek P, Schwarz HP, Aguzzi A. Binding of disease-associated prion protein to plasminogen. Nature 2000; 408: 479–483.
   PubMed Web of Science ®Google Scholar
• Aguzzi A. Prion diseases, blood and the immune system: concerns and reality. Haematologica 2000; 85: 3–10.
   PubMedGoogle Scholar
• Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989; 9: 579–592.
   PubMedGoogle Scholar
• Reblin T, Meyer N, Labeur C, Henne-Bruns D, Beisiegel U. Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques. Atherosclerosis 1995; 113: 179–188.
   PubMedGoogle Scholar
• Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32: 2035–2042.
   PubMed Web of Science ®Google Scholar
• Nielsen LB, Stender S, Kjeldsen K, Nordestgaard BG. Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. Circ Res 1996; 78: 615–626.
   PubMedGoogle Scholar
• Cushing GL, Gaubatz JW, Nava ML, et al. Quantitation and localization of apolipoprotein [a] and B in coronary artery bypass vein grafts resected at reoperation. Arteriosclerosis 1989; 9: 593–603.
   PubMedGoogle Scholar
• Nielsen LB, Gronholdt ML, Schroeder TV, Stender S, Nordestgaard BG. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol 1997; 17: 905–911.
   PubMed Web of Science ®Google Scholar
• Ryan MJ, Emig LL, Hicks GW, et al. Localization of lipoprotein(a) in a monkey model of rapid neointimal growth. Arterioscler Thromb Vasc Biol 1997; 17: 181–187.
   PubMedGoogle Scholar
• Pepin JM, O’Neil JA, Hoff HF. Quantification of apo[a] and apoB in human atherosclerotic lesions. J Lipid Res 1991; 32: 317–327.
   PubMedGoogle Scholar
• Hoff HF, O’Neil J, Yashiro A. Partial characterization of lipoproteins containing apo[a] in human atherosclerotic lesions. J Lipid Res 1993; 34: 789–798.
   PubMedGoogle Scholar
• Callow MJ, Verstuyft J, Tangirala R, Palinski W, Rubin EM. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest 1995; 96: 1639–1646.
   PubMed Web of Science ®Google Scholar
• Fan J, Shimoyamada H, Sun H, Marcovina S, Honda K, Watanabe T. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol 2001; 21: 88–94.
   PubMedGoogle Scholar
• Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from The Committee on Vascular Lesions of the Council of Arteriosclerosis, American Heart Association. Arterioscler Thromb 1994; 14: 840–856.
   Google Scholar
• Auerbach BJ, Cain W, Ansong M, Newton RS, Saxena U, Bisgaier CL. Lipoprotein lipase greatly enhances the retention of lipoprotein(a) to endothelial cell-matrix. Atherosclerosis 1999; 142: 89–96.
   PubMedGoogle Scholar
• Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992; 267: 4143–4151.
   PubMed Web of Science ®Google Scholar
• Nielsen LB, Stender S, Jauhiainen M, Nordestgaard BG. Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta. J Clin Invest 1996; 98: 563–571.
   PubMedGoogle Scholar
• Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801–809.
   PubMed Web of Science ®Google Scholar
• Kostner GM, Bihari-Varga M. Is the atherogenicity of Lp(a) caused by its reactivity with proteoglycans? Eur Heart J 1990; 11 Suppl E: 184–189.
   Google Scholar
• Edelstein C, Italia JA, Klezovitch O, Scanu AM. Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein [a]. J Lipid Res 1996; 37: 1786–1801.
   PubMedGoogle Scholar
• Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ. Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to suben-dothelial matrix. J Clin Invest 1997; 100: 867–874.
   PubMed Web of Science ®Google Scholar
• Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci USA 1998; 95: 12591–12595.
   PubMedGoogle Scholar
• Dudani AK, Ganz PR. Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a). Br J Haematol 1996; 95: 168–178.
   PubMedGoogle Scholar
• Klose R, Fresser F, Kochl S, et al. Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta and gamma chains. J Biol Chem 2000; 275: 38206–38212.
   PubMedGoogle Scholar
• Hoover-Plow J, Khaitan A, Fless GM. Phospholipase A2 modification enhances lipoprotein(a) binding to the subendothelial matrix. Thromb Haemost 1998; 79: 640–648.
   PubMedGoogle Scholar
• Yashiro A, O’Neil J, Hoff HF. Insoluble complex formation of lipoprotein (a) with low density lipoprotein in the presence of calcium ions. J Biol Chem 1993; 268: 4709–4715.
   PubMedGoogle Scholar
• Hofer G, Steyrer E, Kostner GM, Hermetter A. LDL-mediated interaction of Lp[a] with HepG2 cells: a novel fluorescence microscopy approach. J Lipid Res 1997; 38: 2411–2421.
   PubMedGoogle Scholar
• Lawn RM, Pearle AD, Kunz LL, et al. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 1996; 271: 31367–31371.
   PubMedGoogle Scholar
• Yano Y, Seishima M, Tokoro Y, Noma A. Stimulatory effects of lipoprotein(a) and low-density lipoprotein on human umbilical vein endothelial cell migration and proliferation are partially mediated by fibroblast growth factor-2. Biochim Biophys Acta 1998; 1393: 26–34.
   PubMedGoogle Scholar
• Poon M, Zhang X, Dunsky KG, Taubman MB, Harpel PC. Apolipoprotein(a) induces mono-cyte chemotactic activity in human vascular endothelial cells. Circulation 1997; 96: 2514–2519.
   PubMed Web of Science ®Google Scholar
• Ragab MS, Selvaraj P, Sgoutas DS. Oxidized lipoprotein (a) induces cell adhesion molecule Mac-1 (CD 11b) and enhances adhesion of the monocytic cell line U937 to cultured endothe-lial cells. Atherosclerosis 1996; 123: 103–113.
   PubMedGoogle Scholar
• Allen S, Khan S, Tam S, Koschinsky M, Taylor P, Yacoub M. Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity. FASEB J 1998; 12: 1765–1776.
   PubMed Web of Science ®Google Scholar
• Zhao S, Xu D. Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb Res 2000; 100: 501–510.
   PubMed Web of Science ®Google Scholar
• Ganne F, Vasse M, Beaudeux JL, et al. Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins. Consequences for plasmin generation and monocyte adhesion. Thromb Haemost 1999; 81: 594–600.
   PubMedGoogle Scholar
• Zhao SP, Xu DY. Oxidized lipoprotein(a) increases the expression of platelet-derived growth factor-B in human umbilical vein endothelial cells. Clin Chim Acta 2000; 296: 121–133.
   PubMed Web of Science ®Google Scholar
• Galle J, Schneider R, Heinloth A, et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int 1999; 55: 1450–61.
   PubMed Web of Science ®Google Scholar
• Klezovitch O, Edelstein C, Scanu AM. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein (a): evidence for a critical involvement of elements in its C-terminal domain. J Biol Chem 2001 276:46864-46969.
   PubMedGoogle Scholar
• Moeslinger T, Friedl R, Volf I, Brunner M, Koller E, Spieckermann PG. Inhibition of inducible nitric oxide synthesis by oxidized lipoprotein(a) in a murine macrophage cell line. FEBS Lett 2000; 478: 95–99.
   PubMedGoogle Scholar
• Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilatation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 1994; 93: 50–55.
   PubMed Web of Science ®Google Scholar
• Wilmink HW, de Kleijn MJ, Bots ML, et al. Lipoprotein (a) is associated with endothelial function in healthy postmenopausal women. Atherosclerosis 2000; 153: 249–254.
   PubMedGoogle Scholar
• Harpel P, Gordon B, Parker T. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989; 86: 3847–3851.
   PubMedGoogle Scholar
• Rouy D, Koschinsky ML, Fleury V, Chapman J, Anglés-Cano E. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry 1992; 31: 6333–6339.
   PubMed Web of Science ®Google Scholar
• Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303–305.
   PubMed Web of Science ®Google Scholar
• Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 1993; 32: 4628–4633.
   PubMed Web of Science ®Google Scholar
• Rouy D, Grailhe P, Nigon F, Chapman J, Anglés-Cano E: Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator: in vitro studies in a plasma milieu. Arteriosclerosis 1991; 11: 629–638.
   Google Scholar
• Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266: 2459–2465.
   PubMed Web of Science ®Google Scholar
• Levin EG, Miles LA, Fless GM, et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 1994; 14: 438–442.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ren S, Shen GX. Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells. Atherosclerosis 2000; 150: 299–308.
   PubMedGoogle Scholar
• Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98: 2980–2987.
   PubMed Web of Science ®Google Scholar
• Fortunato JE, Bassiouny HS, Song RH, et al. Apolipoprotein (a) fragments in relation to human carotid plaque instability. J Vasc Surg 2000; 32: 555–563.
   PubMed Web of Science ®Google Scholar
• Langman LJ, Cole DE. Homocysteine. Crit Rev Clin Lab Sci 1999; 36: 365–406.
   PubMed Web of Science ®Google Scholar
• Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193–10197.
   PubMed Web of Science ®Google Scholar
• Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW, Sprecher DL. Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 2000; 20: 493–499.
   PubMedGoogle Scholar
• McDowell IF, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J Nutr 2000; 130(2S Suppl): 369S-372S.
   Google Scholar
• Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082–1085.
   PubMed Web of Science ®Google Scholar
• Seed M, Ayres KL, Humphries SE, Miller GJ. Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. Am J Med 2001; 110: 22–27.
   PubMedGoogle Scholar
• Seman LJ, DeLuca C, Jenner JL, et al. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem 1999; 45: 1039–1046.
   PubMedGoogle Scholar
• Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283: 1845–1852.
   PubMed Web of Science ®Google Scholar
• Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998; 44: 2301–2306.
   PubMed Web of Science ®Google Scholar
• Lippi G, Arosio E, Prior M, Guidi G. Biochemical risk factors for cardiovascular disease in an aged male population. Emphasis on emerging pathogens. Angiology 2001; 52: 681–687.
   PubMedGoogle Scholar
• Matsumoto Y, Daida H, Watanabe Y, et al. High level of lipoprotein(a) is a strong predictor for progression of coronary artery disease. J Atheroscler Thromb 1998; 5: 47–53.
   PubMedGoogle Scholar
• Tyrrell J, Cooke T, Reilly M, et al. Lipoprotein [Lp(a)] and peripheral vascular disease. J Intern Med 1992; 232: 349–352.
   PubMedGoogle Scholar
• Widmann MD, Sumpio BE. Lipoprotein (a): a risk factor for peripheral vascular disease. Ann Vasc Surg 1993; 7: 446–451.
   PubMedGoogle Scholar
• Prior M, Arosio E, Ferrari M, Lucchese L, Guidi GC, Bosello O. Lipoprotein(a) and general risk factors in patients with angiographically assessed peripheral arterial disease. Int Angiol 1995; 14: 357–363.
   PubMedGoogle Scholar
• Cantin B, Moorjani S, Dagenais GR, Lupien PJ. Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (the Quebec Cardiovascular Study). Am J Cardiol 1995; 75: 1224–1228.
   PubMedGoogle Scholar
• Cheng SW, Ting AC, Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg 1997; 14: 17–23.
   PubMedGoogle Scholar
• Valentine RJ, Jackson MR, Modrall JG, McIntyre KE, Clagett GP. The progressive nature of peripheral arterial disease in young adults: a prospective analysis of white men referred to a vascular surgery service. J Vasc Surg 1999; 30: 436–444.
   PubMedGoogle Scholar
• Ouriel K. Peripheral arterial disease. Lancet 2001; 358: 1257–1264.
   PubMed Web of Science ®Google Scholar
• Dionyssiou-Asteriou A, Papastamatiou M, Vatalas I, Bastounis E. Serum Lp(a) lipoprotein levels in patients with atherosclerotic occlusive disease of the lower extremities. Eur J Vasc Endovasc Surg 2000; 20: 57–60.
   PubMedGoogle Scholar
• Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 2783–2792.
   PubMedGoogle Scholar
• Cooke JP. The pathophysiology of peripheral arterial disease: rational targets for drug intervention. Vasc Med 1997; 2: 227–30.
   PubMedGoogle Scholar
• Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein (a) and stroke. J Clin Pathol 2000; 53: 487–496.
   PubMed Web of Science ®Google Scholar
• Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986; 17: 942–945.
   PubMedGoogle Scholar
• Jurgens G, Taddei-Peters WC, Koltringer P, et al. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995; 26: 1841–1848.
   PubMedGoogle Scholar
• Watts GF, Mazurkiewicz JC, Tonge K, Nelson V, Warburton FG, Slavin BM. Lipoprotein(a) as a determinant of the severity of angiographically defined carotid atherosclerosis. QJM 1995; 88: 321–326.
   PubMedGoogle Scholar
• Willeit J, Kiechl S, Santer P, et al. Lipoprotein(a) and asymptomatic carotid artery disease. Evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck Study. Stroke 1995; 26: 1582–1587.
   PubMedGoogle Scholar
• Dahl T, Kontny F, Slagsvold CE, et al. Lipoprotein(a), other lipoproteins and hemostatic profiles in patients with ischemic stroke: the relation to cardiogenic embolism. Cerebrovasc Dis 2000; 10: 110–117.
   PubMed Web of Science ®Google Scholar
• Hearn JA, Donohue BC, Ba’albaki H, et al. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992; 69: 736–739.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Imazu M, Yamabe T, Ueda H, Hattori Y, Yamakido M. Risk factors for restenosis after percutaneous transluminal coronary angioplasty: role of lipoprotein (a). Am Heart J 1995; 130: 1168–1173.
   PubMedGoogle Scholar
• Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995; 91: 1403–1409.
   PubMed Web of Science ®Google Scholar
• Miyata M, Biro S, Arima S, et al. High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J 1996; 132: 269–273.
   PubMed Web of Science ®Google Scholar
• Maca T, Ahmadi R, Derfler K, et al. Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? Atherosclerosis 1996; 127: 27–34.
   PubMedGoogle Scholar
• Lippi G, Veraldi GF, Dorucci V, et al. Usefulness of lipids, lipoprotein(a) and fibrinogen measurements in identifying subjects at risk of occlusive complications following vascular and endovascular surgery. Scand J Clin Lab Invest 1998; 58: 497–504.
   PubMed Web of Science ®Google Scholar
• Horie H, Takahashi M, Izumi M, et al. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty. Circulation 1997; 96: 166–73.
   PubMedGoogle Scholar
• Chiarugi L, Prisco D, Antonucci E, et al. Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis 2001; 154: 129–135.
   PubMedGoogle Scholar
• Ryan MJ, Emig LL, Hicks GW, et al. Localization of lipoprotein(a) in a monkey model of rapid neointimal growth. Arterioscler Thromb Vasc Biol 1997; 17: 181–187.
   PubMedGoogle Scholar
• Miner SE, Hegele RA, Sparkes J, et al. Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. Am Heart J 2000; 140: 272–278.
   PubMed Web of Science ®Google Scholar
• Csaszar A, Karadi I, Juhasz E, Romics L. High lipoprotein(a) levels with predominance of high molecular weight apo(a) isoforms in patients with pulmonary embolism. Eur J Clin Invest 1995; 25: 368–370.
   PubMedGoogle Scholar
• Ignatescu M, Kostner K, Zorn G, et al. Plasma Lp(a) levels are increased in patients with chronic thromboembolic pulmonary hypertension. Thromb Haemost 1998; 80: 231–232.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Junker R, Hartmeier M, et al. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999; 100: 743–748.
   PubMed Web of Science ®Google Scholar
• von Depka M, Nowak-Gottl U, Eisert R, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96: 3364–3368.
   PubMed Web of Science ®Google Scholar
• Bandello F, Vigano D’Angelo S, Parlavecchia M, et al. Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion. Thromb Haemost 1994; 72: 39–43.
   PubMedGoogle Scholar
• Ribeaudeau-Saindelle F, Glacet-Bernard A, Lelong F, Coscas G, Soubrane G. Retinal vein occlusion and lipoprotein (a). J Fr Ophtalmol 1998; 21: 245–250.
   PubMedGoogle Scholar
• Lip PL, Blann AD, Jones AF, Lip GY. Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye 1998; 12: 245–251.
   PubMedGoogle Scholar
• Glueck CJ, Bell H, Vadlamani L, et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999; 117: 43–49.
   PubMedGoogle Scholar
• Prisco D, Bertini L, Marcucci R, Poli D. Retinal vein occlusions: diseases for the internist? Ann Ital Med Int 2000; 15: 75–84.
   PubMedGoogle Scholar
• Meekins JW, Pijnenborg R, Hanssens M, van Assche A, McFadyen IR. Immunohistochemical detection of lipoprotein(a) in the wall of placental bed spiral arteries in normal and severe preeclamptic pregnancies. Placenta 1994; 15: 511–524.
   PubMed Web of Science ®Google Scholar
• Berg K, Roald B, Sande H. High Lp(a) lipoprotein level in maternal serum may interfere with placental circulation and cause fetal growth retardation. Clin Genet 1994; 46: 52–56.
   PubMed Web of Science ®Google Scholar
• Marz W, Trommlitz M, Scharrer I, Gross W. Apolipoprotein (a) concentrations are not related to the risk of venous thrombosis. Blood Coagul Fibrinolysis 1991; 2: 595–599.
   PubMed Web of Science ®Google Scholar
• Lippi G, Bassi A, Brocco G, Manzato F, Marini M, Guidi G. Lipoprotein(a) concentration is not associated with venous thromboembolism in a case control study. Haematologica 1999; 84: 726–729.
   PubMedGoogle Scholar
• McColl MD, Sattar N, Ellison J, et al. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis 2000; 11: 225–229.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995; 273: 1269–1273.
   PubMed Web of Science ®Google Scholar
• Lippi G, Guidi G. Relationship between dislipidemia and thrombosis yet unproven. Blood Coagul Fibrinolysis 2001; 12: 81–83.
   PubMedGoogle Scholar
• Kochl S, Fresser F, Lobentanz E, Baier G, Utermann G. Novel interaction of apolipoprotein(a) with beta-2 glycoprotein I mediated by the kringle IV domain. Blood 1997; 90: 1482–1489.
   PubMedGoogle Scholar
• Atsumi T, Khamashta MA, Andujar C, et al. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol 1998; 25: 69–73.
   PubMed Web of Science ®Google Scholar
• Kobayashi T. The level of lipoprotein(a) in human cataractous lens. Jpn J Ophthalmol 2000; 44: 690.
   PubMedGoogle Scholar
• Glueck CJ, Freiberg RA, Fontaine RN, Tracy T, Wang P. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop 2001; 386: 19–33.
   PubMed Web of Science ®Google Scholar
• Sullivan ME, Miller MA, Bell CR, et al. Fibrinogen, lipoprotein (a) and lipids in patients with erectile dysfunction. A preliminary study. Int Angiol 2001; 20: 195–199.
   PubMed Web of Science ®Google Scholar
• Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 1992; 12: 1214–1226.
   PubMedGoogle Scholar
• Kraft HG, Lingenhel A, Kochl S, et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996; 16: 713–719.
   PubMedGoogle Scholar
• Klausen IC, Sjol A, Hansen PS, et al. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Atherosclerosis 1997; 132: 77–84.
   PubMedGoogle Scholar
• Gazzaruso C, Garzaniti A, Buscaglia P, et al. Association between apolipoprotein(a) pheno-types and coronary heart disease at a young age. J Am Coll Cardiol 1999; 33: 157–163.
   PubMedGoogle Scholar
• Marcovina SM, Koschinsky ML. Lipoprotein(a) Concentration and apolipoprotein(a) size. A synergistic role in advanced atherosclerosis? Circulation 1999; 100: 1151–1153.
   Google Scholar
• Brown SA, Morrisett JD, Boerwinkle E, Hutchinson R, Patsch W. The relation of lipoprotein[a] concentrations and apolipoprotein[a] phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993; 13: 1558–1566.
   PubMedGoogle Scholar
• Brazier L, Tiret L, Luc G, et al. Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study. Atherosclerosis 1999; 144: 323–333.
   PubMed Web of Science ®Google Scholar
• Akanji AO. Apo(a) isoforms do not predict risk for coronary heart disease in a Gulf Arab population. Ann Clin Biochem 2000; 37: 360–366.
   PubMed Web of Science ®Google Scholar
• Evans RW, Shpilberg O, Shaten BJ, Ali S, Kamboh MI, Kuller LH. Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial. J Clin Epidemiol 2001; 54: 51–57.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999; 100: 1154–1160.
   PubMed Web of Science ®Google Scholar
• Katsouras CS, Karabina SA, Tambaki AP, et al. Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: association with the severity of clinical presentation in patients with coronary heart disease. J Cardiovasc Risk 2001; 8: 311–317.
   PubMedGoogle Scholar
• Hervio L, Chapman MJ, Thillet J, Loyau S, Angles-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis. Blood 1993; 82: 392–397.
   PubMedGoogle Scholar
• Marcovina SM, Albers JJ, Wijsman E, Zhang ZH, Chapman NH, Kennedy H. Differences in Lp(a) concentrations and apo(a) polymorphs between Black and White Americans. J Lipid Res 1996; 37: 2569–2585.
   PubMedGoogle Scholar
• Paultre F, Pearson TA, Weil HFC, et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 2000; 20: 2619–2624.
   PubMedGoogle Scholar
• Gazzaruso C, Garzaniti A, Geroldi D, Finardi G. Genetics and cardiovascular risk: a role for apolipoprotein(a) polymorphism. Cardiologia 1999; 44: 347–54.
   PubMedGoogle Scholar
• Lagstrom H, Niinikoski H, Lapinleimu H, Viikari J, Ronnemaa T, Simell O. Modifying coronary heart disease risk factors in children: is it ever too early to start? JAMA 1998; 279: 1261.
   PubMedGoogle Scholar
• Ulrich S, Hingorani AD, Martin J, Vallance P. What is the optimal age for starting lipid lowering treatment? A mathematical model. Br Med J 2000; 320: 1134–1140.
   PubMedGoogle Scholar
• Lippi G, Guidi G. Standardization and clinical management of lipoprotein(a) measurements. Clin Chem Lab Med 1998; 36: 5–16.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Lobentanz EM, Konig P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res 1994; 35: 1318–1328.
   PubMedGoogle Scholar
• Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol 1996; 16: 1568–1572.
   PubMedGoogle Scholar
• Sgoutas DS, Tuten T. Effect of freezing and thawing of serum on the immunoassay of lipoprotein(a). Clin Chem 1992; 38: 1873–1877.
   PubMedGoogle Scholar
• Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995; 41: 246–255.
   PubMed Web of Science ®Google Scholar
• Morikawa W, Iki R, Terano T, Funatsu A, Sugiuchi H, Uji Y, Okabe H. Comparison of monoclonal and polyclonal enzyme-linked immunoabsorbent (ELISA) assays for serum Lp(a) and differences in reactivities to Lp(a) phenotypes. J Clin Lab Anal 1995; 9: 173–717.
   PubMedGoogle Scholar
• Lippi G, Ruzzenente O, Facchinetti R, Poli G, Schiesari F, Guidi G. Latex immunonephelometry for lipopoprotein(a) assay. Eur J Lab Med 1994; 2: 23–28.
   Google Scholar
• Schmidt HH, Genschel JC, Wagner S, Manns MP. Quantification of lipoprotein(a): comparison of an automated latex-enhanced nephelometric assay with an immunoenzymometric method. Eur J Clin Chem Clin Biochem 1996; 34: 119–124.
   PubMedGoogle Scholar
• Lippi G, Ruzzenente O, Brentegani C, Pierotti A, Guidi G. Evaluation of the analytical performances of a new fully automated commercial immunonephelometric assay for lipoprotein(a). Clin Chem Lab Med 1998; 36: 719–723.
   PubMedGoogle Scholar
• Hobbs GA, Kaplan IV, Levinson SS. Mechanized lipoprotein(a) assay as a marker for coronary artery disease illustrates the usefulness of high lipoprotein(a) levels. Clin Chim Acta 1998; 274: 1–13.
   PubMedGoogle Scholar
• Gaw A, Brown EA, Gourlay CW, Bell MA. Analytical performance of the Genzyme LipoPro Lp(a) kit for plasma lipoprotein(a)-cholesterol assay. Br J Biomed Sci 2000; 57: 13–18.
   PubMedGoogle Scholar
• Gaw A, Brown EA, Docherty G, Ford I. Is lipoprotein(a)-cholesterol a better predictor of vascular disease events than total lipoprotein(a) mass? A nested case control study from the West of Scotland Coronary Prevention Study. Atherosclerosis 2000; 148: 95–100.
   PubMedGoogle Scholar
• Lippi G, Lo Cascio C, Ruzzenente O, Brentegani C, Guidi G. Significant reduction of the bias among commercial immunoassays for lipoprotein(a) after use of a uniform calibrator. Clin Chim Acta 1996; 256: 125–134.
   PubMedGoogle Scholar
• Lippi G, Brentegani C, Guidi G. Lipoprotein(a): when lack of standardization means misclassification. Eur J Lab Med 1997; 5: 74–77.
   Google Scholar
• Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000; 46: 1956–1967.
   PubMed Web of Science ®Google Scholar
• von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37: 434–439.
   PubMed Web of Science ®Google Scholar
• Maher VMG, Brown G, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274: 1771–1774.
   PubMed Web of Science ®Google Scholar
• Maher VMG, Brown BG. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol 1995; 6: 229–235.
   PubMed Web of Science ®Google Scholar
• Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997; 157: 1170–1176.
   PubMed Web of Science ®Google Scholar
• Thompson GR, Maher VMG, Matthews S, et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995; 345: 811–816.
   PubMed Web of Science ®Google Scholar
• Chobanian AV. Pathophysiology of atherosclerosis. Am J Cardiol 1992; 70: 3G-7G.
   Google Scholar
• Sechi LA, Catena C, Casaccio D, Zingaro L. Lipoprotein (a), haemostatic variables and cardiovascular damage in hypertensive patients. J Hypertens 2000; 18: 709–716.
   PubMedGoogle Scholar
• Sechi LA, Kronenberg F, De Carli S, et al. Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension. JAMA 1997; 277: 1689–1695.
   PubMed Web of Science ®Google Scholar
• Gazzaruso C, Buscaglia P, Garzaniti A, et al. Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension. J Hypertens 1997; 15: 227–235.
   PubMed Web of Science ®Google Scholar
• Catalano M, Perilli E, Carzaniga G, Colombo F, Carotta M, Andreoni S. Lp(a) in hypertensive patients. J Hum Hypertens 1998; 12: 83–89.
   PubMedGoogle Scholar
• Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 1999; 12: 673–681.
   PubMed Web of Science ®Google Scholar
• Martinez MT, Ramos O, Carretero N, et al. Lipoprotein (a) and other risk factors in children with insulin-dependent diabetes mellitus and children without diabetes. Diabete Metab 1994; 20: 522–525.
   PubMedGoogle Scholar
• Kavanagh T, Shephard RJ, Hamm LF, Mertens DJ, Thacker L. Risk profile and health awareness in male offspring of parents with premature coronary heart disease. J Cardiopulm Rehabil 2000; 20: 172–179.
   PubMedGoogle Scholar
• Yamaguchi H, Lee YJ, Daida H, et al. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L-ART). Chem Phys Lipids 1994; 67-68: 399–403.
   Google Scholar
• Kanemitsu S, Tekekoshi N, Murakami E. Effects of LDL apheresis on restenosis after angioplasty. Chem Phys Lipids 1994; 67-68: 339–343.
   Google Scholar
• Adachi H, Niwa A, Shinoda T. Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis. Artif Organs 1995; 19: 1243–1247.
   PubMedGoogle Scholar
• Kanemitsu S, Takekoshi N, Matsui S, et al. Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA): is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA? Ther Apher 1998; 2: 65–70.
   PubMedGoogle Scholar
• Kawasuji M, Sakakibara N, Takemura H, Matsumoto Y, Mabuchi H, Watanabe Y. Coronary artery bypass grafting in familial hypercholesterolemia. J Thorac Cardiovasc Surg 1995; 109: 364–369.
   PubMedGoogle Scholar
• Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996; 132: 23–29.
   PubMed Web of Science ®Google Scholar
• Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med 2000; 160: 2263–2272.
   PubMedGoogle Scholar
• Ylikorkala O, Lim P, Caubel P. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 2000; 22: 622–636.
   PubMedGoogle Scholar
• Sposito AC, Mansur AP, Maranhao RC, Martinez TR, Aldrighi JM, Ramires JA. Triglyceride and lipoprotein (a) are markers of coronary artery disease severity among postmenopausal women. Maturitas 2001; 39: 203–208.
   PubMed Web of Science ®Google Scholar
• van der Mooren MJ, Mijatovic V, van Baal WM, Stehouwer CD. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease. Maturitas 1998; 30: 27–36.
   PubMed Web of Science ®Google Scholar
• Fortmann SP, Marcovina SM. Lipoprotein(a), a clinically elusive lipoprotein particle. Circulation 1997; 95: 295–296.
   PubMedGoogle Scholar
• Ballantyne CM. Current thinking in lipid lowering. Am J Med 1998; 104: 33S-41S.
   Google Scholar
• Pritzker LB. Do lipid lowering drugs reduce the risk of coronary heart disease? Crit Rev Clin Lab Sci 1998; 35: 603–621.
   PubMed Web of Science ®Google Scholar
• Chong PH, Bachenheimer BS. Current, new and future treatments in dyslipidaemia and atherosclerosis. Drugs 2000; 60: 55–93.
   PubMed Web of Science ®Google Scholar
• Hunninghake DB, Stein EA, Mellies MJ. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a. J Clin Pharmacol 1993; 33: 574–580.
   PubMedGoogle Scholar
• Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994; 74: 149–154.
   PubMed Web of Science ®Google Scholar
• Galetta F, Sampietro T, Basta G, Giannasi G, Bionda A. Effects of simvastatin on blood levels of lipoprotein (a). Minerva Med 1995; 86: 299–303.
   PubMedGoogle Scholar
• Dobs AS, Prasad M, Goldberg A, Guccione M, Hoover DR. Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs. Cardiovasc Drugs Ther 1995; 9: 677–684.
   PubMed Web of Science ®Google Scholar
• Ramharack R, Spahr MA, Hicks GW, et al. Gemfibrozil significantly lowers cynomolgus monkey plasma lipoprotein[a]-protein and liver apolipoprotein[a] mRNA levels. J Lipid Res 1995; 36: 1294–1304.
   PubMedGoogle Scholar
• Maggi FM, Biasi GM, Catapano AL. Reduction of Lp(a) plasma levels by bezafibrate. Atherosclerosis 1993; 100: 127–128.
   PubMedGoogle Scholar
• Branchi A, Rovellini A, Fiorenza AM, Sommariva D. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients. Int J Clin Pharmacol Ther 1995; 33: 345–350.
   PubMed Web of Science ®Google Scholar
• Neele DM, Kaptein A, Huisman H, de Wit EC, Princen HM. No effect of fibrates on synthesis of apolipoprotein(a) in primary cultures of cynomolgus monkey and human hepatocytes: apolipoprotein A-I synthesis increased. Biochem Biophys Res Commun 1998; 244: 374–378.
   PubMedGoogle Scholar
• Seed M, O’Connor B, Perombelon N, O’Donnell M, Reaveley D, Knight BL. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 1993; 101: 61–68.
   PubMedGoogle Scholar
• Tanaka K, Hayashi K, Shingu T, et al. Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels. Metabolism 1997; 46: 355–358.
   PubMedGoogle Scholar
• Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000; 160: 1177–1184.
   PubMedGoogle Scholar
• Gavish D, Breslow JL. Lipoprotein(a) reduction by N-acetylcysteine. Lancet 1991; 337: 203–204.
   PubMedGoogle Scholar
• Gilligan S, Owens D, Stinson J, Collins P, Johnson A, Tomkin GH. The effect of reduction of lipoprotein (a) on cellular cholesterol synthesis in non-diabetic and type 2 diabetic subjects. Biochim Biophys Acta 1995; 1254: 187–192.
   PubMedGoogle Scholar
• Scanu AM, Pfaffinger D, Fless GM, Makino K, Eisenbart J, Hinman J. Attenuation of immunologic reactivity of lipoprotein(a) by thiols and cysteine-containing compounds. Structural implications. Arterioscler Thromb 1992; 12: 424–429.
   PubMedGoogle Scholar
• Goldberg A, Alagona P, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000; 85: 1100–1105.
   PubMed Web of Science ®Google Scholar
• Gordon BR. Incorporation of low-density lipoprotein apheresis into the treatment program of patients with severe hypercholesterolemia. Curr Atheroscler Rep 2000; 2: 308–313.
   PubMedGoogle Scholar
• Bambauer R, Schiel R, Latza R. Low density lipoprotein apheresis in treatment of hyperlipi-demia: experience with four different technologies. Ther Apher 2000; 4: 213–217.
   PubMedGoogle Scholar
• Bambauer R, Schiel R, Latza R, Schneidewind JM. LDL-apheresis as long-term treatment in severe hyperlipidemia using differing methods. ASAIO J 1999; 45: 408–412.
   PubMedGoogle Scholar
• Kroon AA, van’t Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000; 152: 519–526.
   PubMedGoogle Scholar
• Dardik BN, Schwartzkopf CD, Stevens DE, Chatelain RE. A quantitative assay for the non-covalent association between apolipoprotein[a] and apolipoprotein B: an alternative measure of Lp[a] assembly. J Lipid Res 2000; 41: 1013–1019.
   PubMedGoogle Scholar
• Ramharack R, Spahr MA, Sekerke CS, et al. CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys. Atherosclerosis 1998; 136: 79–87.
   PubMed Web of Science ®Google Scholar
• Angelin B. Therapy for lowering lipoprotein (a) levels. Curr Opin Lipidol 1997; 8: 337–341.
   PubMedGoogle Scholar
• Kagawa A, Azuma H, Akaike M, Kanagawa Y, Matsumoto T. Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem 1999; 274: 34111–34115.
   PubMedGoogle Scholar
• Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369–382.
   PubMedGoogle Scholar
• Dieplinger H. Lipoprotein(a): the really bad cholesterol? Biochem Soc Trans 1999; 27: 439–447.
   Google Scholar